Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Sanofi
- 14 Nov 2019 Planned End Date changed from 1 Sep 2021 to 1 Jan 2022.
- 14 Nov 2019 Planned primary completion date changed from 1 Sep 2021 to 1 Jan 2022.
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.